PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'Massachusetts General Hospital Cancer Center, Boston, Massachusetts. kflaherty@mgh.harvard.edu.\', \'NCI, NIH, Bethesda, Maryland.\', \'AstraZeneca, Los Angeles, California.\', \'Jonsson Comprehensive Cancer Center at the University of California, Los Angeles (UCLA), Los Angeles, California.\', \'Oncology Center of Excellence, Food and Drug Administration, Silver Spring, Maryland.\']
?:citedBy
  • -1
?:creator
?:doi
  • 10.1158/2159-8290.CD-21-0850
?:doi
?:hasPublicationType
?:journal
  • Cancer discovery
is ?:pmid of
?:pmid
?:pmid
  • 34290074
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • 6.996
?:rankingScore_hIndex
  • 98
?:title
  • Rethinking Cancer Clinical Trial Conduct Induced by COVID-19: An Academic Center, Industry, Government, and Regulatory Agency Perspective.
?:type
?:year
  • 2021

Metadata

Anon_0  
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://purl.org/net/provenance/ns#DataItem>
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://www.w3.org/2004/03/trix/rdfg-1/Graph>
<http://xmlns.com/foaf/0.1/primaryTopic> <https://research.tib.eu/covid-19/entity/34290074>
<http://xmlns.com/foaf/0.1/topic> Anon_0
<http://www.ontologydesignpatterns.org/cp/owl/informationrealization.owl#realizes> <https://research.tib.eu/covid-19/data/entity/34290074>
<http://purl.org/net/provenance/ns#createdBy>
Anon_1   (more)
expand all